{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T06:09:24Z","timestamp":1778479764324,"version":"3.51.4"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Cutaneous T-cell lymphomas (CTCL), including mycosis fungoides (MF) and S\u00e9zary syndrome (SS), remain challenging to diagnose at early stages and to manage durably. Although staging and classification have improved, early MF can mimic benign inflammatory dermatoses, and advanced disease frequently develops resistance to standard therapies, including histone deacetylase (HDAC) inhibitors. Here, we summarize how aberrant DNA methylation and histone modifications contribute to CTCL pathogenesis, promote a permissive tumor microenvironment, and enable immune escape, as well as emerging epigenetic biomarkers, such as microRNA signatures and promoter hypermethylation, that may improve diagnostic accuracy and patient stratification. Finally, we discuss resistance mechanisms linked to epigenetic plasticity and intratumoral heterogeneity and highlight future strategies combining rational drug regimens with longitudinal single-cell profiling to improve the durability of response.<\/jats:p>","DOI":"10.3389\/fcell.2026.1813995","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:29:34Z","timestamp":1778477374000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic dysregulation in mycosis fungoides and s\u00e9zary syndrome"],"prefix":"10.3389","volume":"14","author":[{"given":"Vin\u00edcius de Camargo","family":"Callefi","sequence":"first","affiliation":[{"name":"Real-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isadora","family":"Alves","sequence":"additional","affiliation":[{"name":"Real-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00e9lio C\u00e9zar","family":"De Aquino","sequence":"additional","affiliation":[{"name":"Real-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Brazilian Health Regulatory Agency (Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria - ANVISA)","place":["Bras\u00edlia, Brazil"]},{"name":"Department of Pharmaceutical Assistance and Strategic Inputs (DAF), Ministry of Health, Esplanada dos Minist\u00e9rios","place":["Bras\u00edlia, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia","family":"Cattena","sequence":"additional","affiliation":[{"name":"Real-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuelle","family":"Santos","sequence":"additional","affiliation":[{"name":"Real-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ketelyn","family":"Vasconcelos","sequence":"additional","affiliation":[{"name":"Real-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hebert Fabricio","family":"Culler","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Alberto de P\u00e1dua Covas Lage","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Cancer Institute of the State of S\u00e3o Paulo (ICESP) Oct\u00e1vio Frias de Oliveira","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Cancer Institute of the State of S\u00e3o Paulo (ICESP) Oct\u00e1vio Frias de Oliveira","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana Castello Costa","family":"Girardi","sequence":"additional","affiliation":[{"name":"Laboratory of Renal Physiology and Cardiometabolism, Department of Cardiopneumology, University of S\u00e3o Paulo (FMUSP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Sanches","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of S\u00e3o Paulo Medical School","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alejandro","family":"Murga-Zamalloa","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Illinois at Chicago","place":["Chicago, IL, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Pereira","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Cancer Institute of the State of S\u00e3o Paulo (ICESP) Oct\u00e1vio Frias de Oliveira","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cadiele Oliana","family":"Reichert","sequence":"additional","affiliation":[{"name":"Real-World Evidence Observatory and Lab for Precision Public Health, Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]},{"name":"Laboratory of Medical Investigation in Pathogenesis and Directed Therapy in Onco-Immuno-Hematology (LIM-31), Department of Hematology, Hemotherapy and Cell Therapy - Faculty of Medicine, University of S\u00e3o Paulo (FM-USP)","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis Fungoides\/S\u00e9zary syndrome: validation of the revised international society for cutaneous Lymphomas\/European Organisation for research and treatment of cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1182\/blood-2025-559","article-title":"A new prognostic index (CLIPI) stratifies risk in advanced cutaneous lymphomas: associations with treatment pathways, quality of life and survival","volume":"146","author":"Bashir","year":"2025","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1751561","DOI":"10.1080\/2162402X.2020.1751561","article-title":"Staphylococcus aureus alpha-toxin inhibits CD8 + T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma","volume":"9","author":"Bl\u00fcmel","year":"2020","journal-title":"Oncoimmunology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/bjd\/ljae313","article-title":"Single-cell RNA sequencing comparison of CD4+, CD8+ and T-cell receptor \u03b3\u03b4+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes","volume":"192","author":"Chennareddy","year":"2025","journal-title":"Br. J. Dermatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat. Genet."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/s41409-025-02696-x","article-title":"Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH& G committee","volume":"60","author":"Damaj","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaar5894","DOI":"10.1126\/scitranslmed.aar5894","article-title":"High-throughput sequencing of the T cell receptor \u03b2 gene identifies aggressive early-stage mycosis fungoides","volume":"10","author":"de Masson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"948513","DOI":"10.3389\/fonc.2022.948513","article-title":"Targeted and cellular therapies in lymphoma: mechanisms of escape and innovative strategies","volume":"12","author":"Deshpande","year":"2022","journal-title":"Front. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1007\/s12672-025-04063-0","article-title":"Single-cell sequencing reveals the complexity of cutaneous T-cell lymphoma","volume":"16","author":"Du","year":"2025","journal-title":"Discov. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/bloodadvances.2023012125","article-title":"Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression","volume":"8","author":"Fl\u00e9chon","year":"2024","journal-title":"Blood Adv."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1182\/bloodadvances.2025016347","article-title":"Real-world evidence of duvelisib and romidepsin in relapsed\/refractory peripheral and cutaneous T-cell lymphomas","volume":"9","author":"Ford","year":"2025","journal-title":"Blood Adv."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/cancers13081931","article-title":"Mycosis fungoides and s\u00e9zary syndrome: an integrative review of the pathophysiology, molecular drivers, and targeted therapy","volume":"13","author":"Garc\u00eda-D\u00edaz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/all.70292","article-title":"Staphylococcus aureus augments epithelial skin barrier damage through T cell activation in cutaneous T cell lymphoma","author":"Gluud","year":"2026","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jtct.2024.08.020","article-title":"ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and s\u00e9zary syndrome","volume":"30","author":"Goyal","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.3390\/ijms23073538","article-title":"Epigenetics of cutaneous T-Cell lymphomas","volume":"23","author":"Hara","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/ajh.27735","article-title":"Mycosis fungoides, s\u00e9zary syndrome, and cutaneous b\u2010cell lymphomas: 2025 update on diagnosis, risk\u2010stratification, and management","volume":"100","author":"Hristov","year":"2025","journal-title":"Am. J. Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","article-title":"EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function","volume":"43","author":"Isshiki","year":"2025","journal-title":"Cancer Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1111\/jdv.19987","article-title":"Classifications of cutaneous lymphomas and lymphoproliferative disorders: an update from the EORTC cutaneous lymphoma histopathology group","volume":"38","author":"Kempf","year":"2024","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and s\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fonc.2020.00514","article-title":"New insights into the complex mutational landscape of s\u00e9zary syndrome","volume":"10","author":"Mirza","year":"2020","journal-title":"Front. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/bjd.15422","article-title":"Oncogenic role of microRNA\u2010155 in mycosis fungoides: an in vitro and xenograft mouse model study","volume":"177","author":"Moyal","year":"2017","journal-title":"Br. J. Dermatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-Cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1482866","DOI":"10.3389\/or.2025.1482866","article-title":"Janus kinase inhibitors \u2013 a role for the treatment of cutaneous T-cell lymphomas?","volume":"19","author":"Packer","year":"2025","journal-title":"Oncol. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","article-title":"Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors","volume":"32","author":"Qu","year":"2017","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.1182\/blood-2011-06-358382","article-title":"Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)","volume":"118","author":"Ralfkiaer","year":"2011","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1182\/blood.2025029628","article-title":"A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification","volume":"146","author":"Scarisbrick","year":"2025","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/bjh.15547","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR\u2010155, co\u2010ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T\u2010cell lymphoma","volume":"183","author":"Seto","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.jid.2023.12.010","article-title":"Romidepsin and afatinib abrogate jak\u2013signal transducer and activator of transcription signaling and elicit synergistic antitumor effects in cutaneous T-Cell lymphoma","volume":"144","author":"Shih","year":"2024","journal-title":"J. Investigative Dermatology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10555-024-10167-w","article-title":"Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy","volume":"43","author":"Singh","year":"2024","journal-title":"Cancer Metastasis Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"20980","DOI":"10.1073\/pnas.1012525107","article-title":"Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas","volume":"107","author":"Sneeringer","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1408614","DOI":"10.3389\/fonc.2024.1408614","article-title":"Single-cell RNA and T-cell receptor sequencing unveil mycosis fungoides heterogeneity and a possible gene signature","volume":"14","author":"Srinivas","year":"2024","journal-title":"Front. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/S2352-3026(25)00322-9","article-title":"Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or s\u00e9zary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"13","author":"Stadler","year":"2026","journal-title":"Lancet Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1002\/mog2.59","article-title":"Epigenetic regulation in cancer therapy: from mechanisms to clinical advances","volume":"3","author":"Tao","year":"2024","journal-title":"MedComm \u2013 Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1182\/blood.2019004256","article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","volume":"139","author":"Tensen","year":"2022","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/febs.70208","article-title":"CRISPR \u2010Cas9 screen reveals that inhibition of enhancer of zeste homolog 2 sensitizes malignant T cells to dimethyl\u2010fumarate\u2010induced cell death","volume":"293","author":"Teubner","year":"2026","journal-title":"FEBS J."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1576781","DOI":"10.3389\/fonc.2025.1576781","article-title":"Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulation","volume":"15","author":"Tian","year":"2025","journal-title":"Front. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2023021671","article-title":"Staphylococcus aureus induces drug resistance in cancer T cells in s\u00e9zary syndrome","volume":"143","author":"Vadivel","year":"2024","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-Cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"104126","DOI":"10.1016\/j.lpm.2022.104126","article-title":"Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification","volume":"51","author":"Willemze","year":"2022","journal-title":"Presse Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jid.2020.05.110","article-title":"Cutaneous T-Cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3K\u03b1\/\u03b4 and HDAC","volume":"141","author":"Wu","year":"2021","journal-title":"J. Investigative Dermatology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s12185-022-03470-1","article-title":"The role of epigenetics in T-cell lymphoma","volume":"116","author":"Yamagishi","year":"2022","journal-title":"Int. J. Hematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.jid.2017.10.036","article-title":"Dual role of EZH2 in cutaneous Anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment","volume":"138","author":"Yi","year":"2018","journal-title":"J. Investigative Dermatology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"663961","DOI":"10.3389\/fonc.2021.663961","article-title":"Epigenetics in the pathogenesis and treatment of cutaneous T-Cell lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1529239","DOI":"10.3389\/fimmu.2025.1529239","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/cancers18071169","article-title":"Pathology of cutaneous T cell lymphoma: a narrative review","volume":"18","author":"Zhang","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e009099","DOI":"10.1136\/jitc-2024-009099","article-title":"Cantharidin overcomes IL-2R\u03b1 signaling-mediated vorinostat resistance in cutaneous T-cell lymphoma through reactive oxygen species","volume":"12","author":"Zhu","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1813995\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:29:35Z","timestamp":1778477375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1813995\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":51,"alternative-id":["10.3389\/fcell.2026.1813995"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1813995","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1813995"}}